NCT00856388 · REGISTRY CONDITION SEARCH

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: COMPLETED
Registry last update: 2019-11-13

This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow failure disorders. Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect)

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Day 100 TRM

→

outcome · POSTED

Median Time to ANC Engraftment

→

outcome · POSTED

Median Time to Platelet Engraftment

→

outcome · POSTED

Rate of Complete Donor Chimerism - Blood

→

outcome · POSTED

Rate of Complete Donor Chimerism - Blood

→

outcome · POSTED

Acute GVHD Grade III-IV

→

outcome · POSTED

1 yr Extenstive Chronic GVHD

→

outcome · POSTED

3 yr Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Diagnosis of a histology documented hematologic malignancy or marrow disorder * Bone marrow failure disorders and other non-malignant hematologic or immunologic disorders: * Acquired bone marrow failure disorders include aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH): * Primary allogeneic hematopoietic stem cell transplantation (HSCT) is appropriate for selected patients with severe aplastic anemia; however, patients with aplastic anemia must have failed at least one cycle of standard immunosuppressive therapy with calcineurin inhibitor plus anti-thymocyte globulin (ATG) if a fully-matched donor is not available * Patients with PNH must have a history of thrombosis related to PNH * Hereditary bone marrow failure disorders include Fanconi anemia or related chromosomal breakage syndrome dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, Kostmann syndrome, congenital amegakaryocytic thrombocytopenia: * Fanconi anemia or related chromosomal breakage syndrome: positive chromosome breakage analysis using diepoxybutane (DEB) or mitomycin C if applicable * Dyskeratosis: diagnosis is supported by using either telomerase reverse transcriptase (TERC) gene mutation in autosomal dominant Dyskeratosis Congenita or Xlinked DKC1 gene mutation * Other non-malignant hematologic or immunologic disorders that require transplantation * Quantitative or qualitative congenital platelet disorders (including but not limited to congenital amegakaryocytopenia, absent-radii syndrome, Glanzmann's thrombasthenia) * Quantitative or qualitative congenital neutrophil disorders (including but not limited to chronic granulomatous disease, congenital neutropenia) * Congenital primary immunodeficiencies (including but not limited to Severe Combined Immunodeficiency Syndrome, Wiskott-Aldrick syndrome, CD40 ligand deficiency, T-cell deficiencies) * Acute leukemias: * Subjects must be ineligible for conventional myeloablative transplantation; * Resistant or recurrent disease after at least one standard combination chemotherapy regime or first remission patients at high risk of relapse OR First remission patients at high risk of relapse: * Acute myeloid leukemia (AML)- antecedent myelodysplastic syndrome, secondary AML, high risk cytogenetic abnormalities or normal cytogenetics with high-risk molecular features (e.g. Flt3-ITD mutation, mixed-lineage leukemia \[MLL\], wildtype NPM1); * Acute lymphocytic leukemia (ALL)- high or standard risk ALL * Chronic Myeloid Leukemia (CML): * Chronic phase (intolerant or unresponsive to imatinib and/or other tyrosine kinase inhibitors), second chronic phase or accelerated phase who are ineligible for conventional myeloablative transplantation * Myeloproliferative and myelodysplastic syndromes (MDS): * Myelofibrosis (with/without splenectomy) with intermediate to high risk features * Advanced polycythemia vera not responding to standard therapy * MDS with an international prostate symptom score (IPSS) score of Int-2 or higher * MDS with lower IPSS scores Int-1 or less with severe clinical features such as severe neutropenia or thrombocytopenia or high risk chromosome abnormalities such as monosomy 7 * Secondary massively parallel signature sequencing (MPSS) with any IPSS scores * Chronic myelomoncytic leukemia * Lymphoproliferative disease: * Chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin lymphoma (NHL) (recurrent or persistent) fludarabine refractory or with less than 6 months duration of complete response (CR) between courses of conventional therapy * Multiple myeloma, progressive disease after autologous stem cell transplant or as planned tandem (allogeneic transplant after prior autologous stem cell transplant) * Waldenstroms macroglobulinemia (failed one standard regimen) * High grade NHL and diffuse large B-cell lymphoma (DLBCL) * Not eligible for conventional myeloablative HSCT OR failed autologous HSCT * First remission lymphoblastic lymphoma, or small, non-cleaved cell lymphoma or mantle cell lymphoma * Hodgkin disease: * Relapsed or refractory after front-line therapy * Failed or were not eligible for autologous transplantation * Failed prior autotransplant * Age \>= 3 and =\< 75 years for blood and bone marrow transplants and age \>= 3, \< 60 for cord blood transplants * No serious uncontrolled psychiatric illness * No concomitant active malignancy other than non-melanoma skin cancer * Non-pregnant and non-nursing women (women or men with reproductive potential should agree to use an effective means of birth control) * Patients may have received prior autologous bone marrow transplant (BMT) or prior myeloablative allogeneic BMT (at least 60 days have elapsed) * At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery * Informed consent * DONOR: Permissible HLA matching: Related donors- single antigen mismatch at HLA A, B or DRB 1; unrelated donors- a single antigen mismatch at HLA A, B, or C, +/- additional single allele level mismatch at A, B, C or DRB1; cord blood \>= 4 out of 6 antigen match at HLA A, B, DRB1) * DONOR: Compatibility at the four most informative HLA loci: A, B, C and DRB1 are important for reducing the risk of GVHD and successful transplant outcomes; the A, B, C and DRB1 loci comprise 8 possible alleles (a haplotype being inherited from each parent); one additional locus, HLA-DQ, is also typed to ascertain haplotypes and assist in the search for a compatible donor; however mismatching at DQ has not been shown to be associated with adverse outcomes; high resolution molecular typing (at the allele level) is now the standard of care for unrelated donor searches and allows greater refinement of the search strategy * DONOR: Matched related donor: a single antigen mismatch at A, B, or the DR transplant from a family member is associated with a higher risk of GVHD but similar overall survival when compared to full identity at these 3 regions; related donor/recipient pairs must be matched at 5 of 6 HLA antigens (A, B, DRBl) * DONOR: Unrelated donor: when evaluating patients for unrelated donor transplant, a higher degree of matching is preferred due to minimize the risk of GVHD; the A, B, C, DRB1 and DQ loci, comprising 10 possible alleles, will be typed routinely for all unrelated transplants; given the higher risk of TRM in mismatched transplants, RIT is often the best way to mitigate the risk; evolving data from the National Marrow Donor Program now makes it possible to estimate the risks of donor-recipient HLA mismatch at the allele or antigen level; the higher risk from HLA-mismatching must be carefully assessed with respect to the clinical urgency and the patient's risk by the transplant physician; antigen level mismatches at DQ are inconsequential to transplant outcomes and are ignored with respect to donor selection for the purposes of this protocol, with matching requirements confined to the 8 loci involving HLA A, B, C and DRB1; for the purpose of this protocol, a single antigen mismatch at HLA A, B, or C, with or without additional single allele level mismatch may participate in this protocol for voluntary unrelated donors (blood or marrow); patients must be at least antigen-level matched at DRB1 * DONOR: If a patient has no suitable family donor matched for 5 of 6 HLA antigens (A, B, DRB1) and no suitable unrelated donor is identified or for reasons of urgency, the patient can be considered a candidate for cord blood transplant, provided a cord blood donor is identified with a \>= 4 out of 6 antigen match at HLA A, B, DRB1 antigens; the cord blood product must provide a minimum of 2 x 10\^7 nucleated cells/kg, test negative for HIV and Hepatitis A, Band C, and sterility assays have no growth; the cord blood products are located through the National Marrow Donor Program, the American Registry, or the Bone Marrow Donor Worldwide or other established registries, and may be stored in the N.Y Placental Cord Blood Bank, the St. Louis Cord Blood Bank, or any of the established, registered International blood and marrow banks * DONOR: Donor must be healthy and have nonreactive test results for all infectious disease assays as required by state and federal regulations; donors who screen seropositive for hepatitis and/or syphilis must be cleared by infectious disease consultation * DONOR: The donor must have no uncontrolled cardiopulmonary, renal, endocrine, hepatic or psychiatric disease to render donation unsafe * DONOR: The donor must be able to give informed consent for peripheral blood stem cell collection or bone marrow collection * DONOR: Syngeneic donors are not eligible * DONOR: Donors who have poor peripheral venous access, may require central venous line placement for stem cell apheresis Exclusion Criteria: * Uncontrolled central nervous system (CNS) disease (for hematologic malignancies) * Karnofsky (adult) or Lansky (for =\< 16 years) performance status =\< 50% * Diffusing capacity of the lung for carbon monoxide (DLCO) less than 40% predicted, corrected for hemoglobin (Hb) and/or alveolar ventilation * Cardiac: left ventricular ejection fraction less than 40% * Bilirubin \>= 3 x upper limit of normal * Liver alkaline phosphatase \>= 3 x upper limit of normal * Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvate transaminase (SGPT) \>= 3 x upper limit of normal * Child's class B and C liver failure * Calculated creatinine clearance \< 40 cc/min by the modified Cockcroft-Gault formula for adults or the Schwartz formula for pediatrics * Patients who have received maximally allowed doses (given in 2 Gy fractions, or equivalent) of previous radiation therapy to various organs as follows: * Mediastinum 40 Gy * Heart (any volume) 36 Gy * Whole lungs 12 Gy * Small bowel (any volume) 46 Gy * Kidneys 12 Gy * Whole liver 20 Gy * Spinal cord (any volume) 36 Gy * Whole brain 30 Gy Enrollment of patients who previously receive higher than allowed dose of radiation to a small volume of lungs, liver, and brain will be determine by the discretion of the radiation oncologist on the study * Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or other condition which, in the opinion of treating physician, would make this protocol unreasonably hazardous for the patient * Human immunodeficiency virus (HIV) positive * Patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening * Females of childbearing potential with a positive pregnancy test
healthy Volunteers: false
maximum Age: 75 Years
minimum Age: 3 Years
sex: ALL
std Ages: CHILD
ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0. Note: \*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.
intervention Names
Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: anti-thymocyte globulin
label
Treatment (Reduced intensity allogeneic stem cell transplant)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (Reduced intensity allogeneic stem cell transplant)
description
Given IV
name
fludarabine phosphate
other Names
2-F-ara-AMP
Beneflur
Fludara
type
DRUG
arm Group Labels
Treatment (Reduced intensity allogeneic stem cell transplant)
description
Given IV
name
melphalan
other Names
Alkeran
CB-3025
L-PAM
L-phenylalanine mustard
L-Sarcolysin
type
DRUG
arm Group Labels
Treatment (Reduced intensity allogeneic stem cell transplant)
description
Undergo total-body irradiation
name
total-body irradiation
other Names
TBI
type
RADIATION
arm Group Labels
Treatment (Reduced intensity allogeneic stem cell transplant)
description
Undergo allogeneic stem cell transplantation
name
allogeneic hematopoietic stem cell transplantation
type
PROCEDURE
arm Group Labels
Treatment (Reduced intensity allogeneic stem cell transplant)
description
Given IV
name
anti-thymocyte globulin
other Names
ATG
ATGAM
lymphocyte immune globulin
Thymoglobulin
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 62
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.
measure
Day 100 TRM
time Frame
First 100 days

secondary Outcomes

description
Median Time to ANC Engraftment Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.
measure
Median Time to ANC Engraftment
time Frame
Days 30
description
Median Time to Platelet Engraftment Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.
measure
Median Time to Platelet Engraftment
time Frame
Day 100
description
Rate of Complete Donor Chimerism - Blood Summarized using standard descriptive statistics.
measure
Rate of Complete Donor Chimerism - Blood
time Frame
Day 30
description
Rate of Complete Donor Chimerism - Blood Summarized using standard descriptive statistics.
measure
Rate of Complete Donor Chimerism - Blood
time Frame
Day 100
description
Acute GVHD grade III-IV Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.
measure
Acute GVHD Grade III-IV
time Frame
Up to day 100
description
1 yr Extensive Chronic GVHD Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.
measure
1 yr Extenstive Chronic GVHD
time Frame
Up to 4.5 years
description
3 yr Overall Survival estimated using the Kaplan-Meier method.
measure
3 yr Overall Survival
time Frame
Up to 4.5 years

Full study description

brief Summary: This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow failure disorders. Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect)
detailed Description: PRIMARY OBJECTIVES: I. To determine the transplant related mortality (TRM) of this reduced intensity transplantation (RIT) combination in a patient population that is usually not eligible for a full myeloablative allogeneic transplant. SECONDARY OBJECTIVES: I. To evaluate engraftment, safety, clinical response, evidence of graft-versus-malignancy effect/graft-versus-host disease (GVHD) and overall outcomes of treatment with our RIT regimen across a variety of hematological conditions. OUTLINE: Patients receive fludarabine phosphate intravenously (IV) over 30 minutes on days -5 to -2 and melphalan\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0. Note: \*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan. After completion of study treatment, patients are followed up periodically.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-30e50f1342caed4098f8
requested nct id
NCT00856388
primary nct id
NCT00856388
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
f4c958c4911dd90e496b6f01ce287de6b5fdc3e529823472bcd71d2aca8e9fef
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-30e50f1342caed4098f8
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00856388
occurrences
context exact
NCT00856388
end
11
exact text
NCT00856388
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/622/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cae0eece694215535b16b0252470c3fc6e958200adb0be2bba59dbd706147c83
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-5f449b541a0d6ee2a352
requested nct id
NCT00856388
primary nct id
NCT00856388
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
payload sha256
f77b42809ddd57e3c66407108b813b28ac02e347edff4312b7362264ae4fc90d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-5f449b541a0d6ee2a352
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00856388
occurrences
context exact
NCT00856388
end
11
exact text
NCT00856388
start
0
offset unit
unicode_code_points
query cond
Acute Undifferentiated Leukemia
query disease state id
ds-acute-undifferentiated-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
source json pointer
/studies/33/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cae0eece694215535b16b0252470c3fc6e958200adb0be2bba59dbd706147c83
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-ab8a9485887c3a9461bc
requested nct id
NCT00856388
primary nct id
NCT00856388
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
payload sha256
a8a8e8506eef061da4e01567d1e0b3ecd2fb122f75333411579c95b6a8733e31
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-ab8a9485887c3a9461bc
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00856388
occurrences
context exact
NCT00856388
end
11
exact text
NCT00856388
start
0
offset unit
unicode_code_points
query cond
Juvenile Myelomonocytic Leukemia
query disease state id
ds-juvenile-myelomonocytic-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
source json pointer
/studies/89/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cae0eece694215535b16b0252470c3fc6e958200adb0be2bba59dbd706147c83
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f9481c7ecbf99db64869
requested nct id
NCT00856388
primary nct id
NCT00856388
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Chronic+Myeloid+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
payload sha256
e583de4f8437dbe13f739a21d8beca04668a5f3637d68c071d41e3a18e4dda83
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f9481c7ecbf99db64869
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00856388
occurrences
context exact
NCT00856388
end
11
exact text
NCT00856388
start
0
offset unit
unicode_code_points
query cond
Childhood Chronic Myeloid Leukemia
query disease state id
ds-chronic-myeloid-leukemia-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
source file sha256
193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
source json pointer
/studies/34/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cae0eece694215535b16b0252470c3fc6e958200adb0be2bba59dbd706147c83
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Chronic+Myeloid+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f9bc42ae36eebcf9e9c6
requested nct id
NCT00856388
primary nct id
NCT00856388
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Myelodysplastic+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
payload sha256
7a55722f1163155892b8008e0ebef3e0b6a9683ad3bdadd13d61348819999372
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f9bc42ae36eebcf9e9c6
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00856388
occurrences
context exact
NCT00856388
end
11
exact text
NCT00856388
start
0
offset unit
unicode_code_points
query cond
Childhood Myelodysplastic Neoplasms
query disease state id
ds-myelodysplastic-neoplasms-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-myelodysplastic-neoplasms-000.json
source file sha256
a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
source json pointer
/studies/38/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cae0eece694215535b16b0252470c3fc6e958200adb0be2bba59dbd706147c83
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Myelodysplastic+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice